Results of Phase 3 Study of Immunotherapy Prostvac Due at Year’s End – Prostate Cancer News Today
Prostate Cancer News Today |
Results of Phase 3 Study of Immunotherapy Prostvac Due at Year's End
Prostate Cancer News Today Bavarian Nordic announced that full data from its Phase 3 study assessing the effectiveness of its immunotherapy candidate, Prostvac, to improve survival in people with metastatic castration-resistant prostate cancer (mCRPC) is now expected late in … |
